- ICH GCP
- Rejestr badań klinicznych w USA
- Badanie kliniczne NCT07278336
A Study to Assess Adverse Events, Change in Disease Activity and How Intravenous (IV) ABBV901 Moves Through the Body Alone or in Combination With Other Anticancer Drugs in Adult Participants With Ovarian Cancer
A Phase 1 First-in-Human, Open-Label Study Evaluating Safety, Pharmacokinetics, and Efficacy of ABBV-901 as a Monotherapy and in Combination in Adult Subjects With Ovarian Cancer
Ovarian cancer (OC) is a lethal disease. The purpose of this study is to assess the safety, pharmacokinetics and efficacy of ABBV901, alone or in combination with other anticancer drugs, in participants with ovarian cancer.
ABBV901 is an investigational drug for the treatment of ovarian cancer. This study has 6 parts where participants will receive ABBV-901, alone or in combination with other anticancer therapies. Around 285 participants will be enrolled in the study at approximately 45 sites around the world.
In part 1, participants will receive escalating doses of intravenous (IV) ABBV-901 alone. In part 2, participants will receive 1 of 3 doses of IV ABBV-901 alone to determine the optimized dose. In part 3, participants will receive escalating doses of IV ABBV-901 in combination with IV bevacizumab. In part 4, participants will receive recommended doses for expansion of IV ABBV-901 combination with IV bevacizumab. in Part 5, participants will receive escalating doses of IV ABBV-901 in combination with IV carboplatin and IV bevacizumab and in part 6, participants will receive recommended doses for expansion of IV ABBV-901 combination with IV carboplatin and IV bevacizumab. The total study duration will be approximately 3 years.
There may be higher treatment burden for participants in this trial compared to their standard of care. Participants will attend regular visits during the study at a hospital or clinic and may require frequent medical assessments, blood tests, and scans.
Przegląd badań
Status
Warunki
Interwencja / Leczenie
Typ studiów
Zapisy (Szacowany)
Faza
- Faza 1
Kontakty i lokalizacje
Kontakt w sprawie studiów
- Nazwa: ABBVIE CALL CENTER
- Numer telefonu: 844-663-3742
- E-mail: abbvieclinicaltrials@abbvie.com
Lokalizacje studiów
-
-
New South Wales
-
Blacktown, New South Wales, Australia, 2148
- Rekrutacyjny
- Blacktown Hospital /ID# 282426
-
-
Victoria
-
Clayton, Victoria, Australia, 3168
- Rekrutacyjny
- Monash Health - Monash Medical Centre - Clayton /ID# 281468
-
Melbourne, Victoria, Australia, 3000
- Rekrutacyjny
- Peter MacCallum Cancer Centre. /ID# 281751
-
-
-
-
Pays de la Loire Region
-
Saint-Herblain, Pays de la Loire Region, Francja, 44805
- Rekrutacyjny
- Institut De Cancerologie De L'Ouest - Site Rene Gauducheau /ID# 280684
-
-
Rhone
-
Lyon, Rhone, Francja, 69373
- Rekrutacyjny
- Centre Leon Berard /ID# 280575
-
-
-
-
-
Barcelona, Hiszpania, 08035
- Rekrutacyjny
- Hospital Universitari Vall d Hebron /ID# 280442
-
Madrid, Hiszpania, 28040
- Rekrutacyjny
- Hospital Universitario Fundacion Jimenez Diaz /ID# 280440
-
Madrid, Hiszpania, 28050
- Rekrutacyjny
- Hospital Universitario HM Sanchinarro /ID# 280439
-
-
Madrid
-
Majadahonda, Madrid, Hiszpania, 28222
- Rekrutacyjny
- Hospital Universitario Puerta de Hierro - Majadahonda /ID# 280459
-
-
-
-
-
Haifa, Izrael, 3109601
- Rekrutacyjny
- Rambam Health Care Campus /ID# 278418
-
Jerusalem, Izrael, 91120
- Rekrutacyjny
- Hadassah Medical Center-Hebrew University /ID# 278420
-
-
Tel Aviv
-
Ramat Gan, Tel Aviv, Izrael, 5265601
- Rekrutacyjny
- The Chaim Sheba Medical Center /ID# 278416
-
-
-
-
Chiba
-
Kashiwa-shi, Chiba, Japonia, 277-8577
- Rekrutacyjny
- National Cancer Center Hospital East /ID# 278604
-
-
Saitama
-
Hidaka, Saitama, Japonia, 350-1298
- Rekrutacyjny
- Saitama Medical University International Medical Center /ID# 278437
-
-
Shizuoka
-
Sunto-gun, Shizuoka, Japonia, 411-8777
- Rekrutacyjny
- Shizuoka Cancer Center /ID# 278538
-
-
-
-
-
Lisbon, Portugalia, 1649-035
- Rekrutacyjny
- Unidade Local de Saude de Santa Maria /ID# 280296
-
Porto, Portugalia, 4200-072
- Rekrutacyjny
- Instituto Portugues de Oncologia do Porto Francisco Gentil /ID# 280293
-
-
-
-
California
-
Duarte, California, Stany Zjednoczone, 91010
- Rekrutacyjny
- City of Hope National Medical Center /ID# 281381
-
Irvine, California, Stany Zjednoczone, 92618
- Rekrutacyjny
- City of Hope - Orange County Lennar Foundation Cancer Center /ID# 280914
-
-
Colorado
-
Denver, Colorado, Stany Zjednoczone, 80218
- Rekrutacyjny
- Sarah Cannon Research Institute at HealthONE /ID# 278785
-
-
Illinois
-
Chicago, Illinois, Stany Zjednoczone, 60637
- Rekrutacyjny
- University of Chicago Medical Center /ID# 278295
-
-
Nebraska
-
Omaha, Nebraska, Stany Zjednoczone, 68198
- Rekrutacyjny
- University Of Nebraska Medical Center /ID# 281020
-
-
Texas
-
San Antonio, Texas, Stany Zjednoczone, 78229
- Rekrutacyjny
- NEXT Oncology - San Antonio /ID# 278606
-
-
Utah
-
West Valley City, Utah, Stany Zjednoczone, 84119
- Rekrutacyjny
- Start Mountain Region /ID# 278609
-
-
Virginia
-
Fairfax, Virginia, Stany Zjednoczone, 22031
- Rekrutacyjny
- Next Virginia /ID# 278607
-
-
-
-
-
Taipei, Tajwan, 112
- Rekrutacyjny
- Taipei Veterans General Hospital /ID# 281349
-
Taipei, Tajwan, 100
- Rekrutacyjny
- National Taiwan University Hospital /ID# 280701
-
-
Kryteria uczestnictwa
Kryteria kwalifikacji
Wiek uprawniający do nauki
Akceptuje zdrowych ochotników
Płeć kwalifikująca się do nauki
Opis
Inclusion Criteria:
- Diagnosis of an advanced or unresectable malignant high grade serous epithelial ovarian, fallopian tube, and primary peritoneal cancers (EOC), fallopian tube or primary peritoneal cancer by histology (World Health Organization [WHO] criteria).
- Participants enrolled in backfill (Part 1) must provide consent to paired fresh biopsies which are pretreatment and on-treatment tumor biopsies from the same tumor lesion.
For Parts 1-4:
- Participants must be considered platinum resistant or platinum ineligible. Platinum resistant disease is defined as radiographic progression within 6 months (up to 182 days) after the last dose of the most recent platinum therapy).
For Parts 5-6:
- Participants will have platinum-sensitive disease defined as radiographic progression > 6 months from last dose of platinum-based chemotherapy. Note: Progression should be calculated from the date of the last administered dose of platinum therapy to the date of the radiographic imaging showing progression.
Exclusion Criteria:
- Ovarian Cancer (OC) with histologies other than high grade serous OC including endometrioid, low grade, mucinous, carcinosarcoma or sarcomatous histology, mixed tumors or low grade/borderline ovarian tumor.
- Participants with platinum refractory disease.
- Prior therapy with an antibody-drug conjugate containing a topoisomerase inhibitor.
- Prior history of Grade >= 2 interstitial lung disease (ILD) or pneumonitis.
- Prior history of Grade 2 >= 2 ILD or pneumonitis or any evidence of active ILD or pneumonitis on Screening chest computed tomography (CT) scan.
For Parts 3-6:
- History of Grade 3/4 adverse events that, in the opinion of the investigator, are attributed to bevacizumab.
- History of clinically significant cardiac disease including CHF Class II or higher NYHA; active coronary artery disease, MI within 6 months prior to study entry; unevaluated new onset angina within 3 months or unstable angina (angina symptoms at rest) or cardiac arrhythmias requiring antiarrhythmic therapy (beta blockers or digoxin are permitted).
- Echocardiogram with ejection fraction <= 50% and no other clinically significant cardiac abnormalities that in the opinion of the investigator, would increase the participants susceptibility to cardiac toxicity.
For Parts 5-6:
- Participants who had prior allergic reaction to platinum containing compound.
Plan studiów
Jak projektuje się badanie?
Szczegóły projektu
- Główny cel: Leczenie
- Przydział: Randomizowane
- Model interwencyjny: Zadanie sekwencyjne
- Maskowanie: Brak (otwarta etykieta)
Broń i interwencje
Grupa uczestników / Arm |
Interwencja / Leczenie |
|---|---|
|
Eksperymentalny: Part 1: ABBV-901 Dose Escalation
Participants will receive escalating doses of ABBV-901 alone, as part of the approximately 3 year study duration. |
Intravenous (IV) |
|
Eksperymentalny: Part 2: ABBV-901 Optimization Dose A
Participants will receive ABBV-901 dose A alone, as part of the approximately 3 year study duration. |
Intravenous (IV) |
|
Eksperymentalny: Part 2: ABBV-901 Optimization Dose B
Participants will receive ABBV-901 dose B alone, as part of the approximately 3 year study duration. |
Intravenous (IV) |
|
Eksperymentalny: Part 2: ABBV-901 Optimization Dose C
Participants will receive ABBV-901 dose C alone, as part of the approximately 3 year study duration. |
Intravenous (IV) |
|
Eksperymentalny: Part 3: ABBV-901 + Bevacizumab Escalation
Participants will receive escalating doses of ABBV-901 in combination Bevacizumab, as part of the approximately 3 year study duration. |
Intravenous (IV) Intravenous (IV) |
|
Eksperymentalny: Part 4: ABBV-901 + Bevacizumab Expansion
Participants will receive the recommended doses for expansion doses of ABBV-901 in combination Bevacizumab, as part of the approximately 3 year study duration. |
Intravenous (IV) Intravenous (IV) |
|
Eksperymentalny: Part 5: ABBV-901 + Carboplatin + Bevacizumab Escalation
Participants will receive escalating doses of ABBV-901 in combination with Carboplatin & Bevacizumab, as part of the approximately 3 year study duration. |
Intravenous (IV) Intravenous (IV) Intravenous (IV) |
|
Eksperymentalny: Part 6: ABBV-901 + Carboplatin + Bevacizumab Expansion
Participants will receive the recommended doses for expansion doses of ABBV-901 in combination with Carboplatin & Bevacizumab, as part of the approximately 3 year study duration. |
Intravenous (IV) Intravenous (IV) Intravenous (IV) |
Co mierzy badanie?
Podstawowe miary wyniku
Miara wyniku |
Opis środka |
Ramy czasowe |
|---|---|---|
|
Number of Participants with Adverse Events (AE)
Ramy czasowe: Up to Approximately 3 Years
|
An adverse event (AE) is defined as any untoward medical occurrence in a participant or clinical investigation participant administered a pharmaceutical product, and which does not necessarily have a causal relationship with this treatment. |
Up to Approximately 3 Years
|
|
Overall Response (as assessed by the investigator)
Ramy czasowe: Up to Approximately 3 Years
|
Overall response is defined as participants achieving confirmed complete response (CR) or partial response (PR) per Response Evaluation Criteria in Solid Tumors (RECIST) Version 1.1 as assessed by the investigator. |
Up to Approximately 3 Years
|
Miary wyników drugorzędnych
Miara wyniku |
Opis środka |
Ramy czasowe |
|---|---|---|
|
Overall Response (as assessed by independent central review)
Ramy czasowe: Up to Approximately 3 Years
|
Overall response is defined as participants achieving confirmed complete response (CR) or partial response (PR) per Response Evaluation Criteria in Solid Tumors (RECIST) Version 1.1 as assessed by independent central review (ICR). |
Up to Approximately 3 Years
|
|
Duration of Response (DOR)
Ramy czasowe: Up to Approximately 3 Years
|
DOR is defined for participants achieving a confirmed PR or better as the time from the initial response of PR (or better) per investigator review according to RECIST Version 1.1 criteria to disease progression or death of any cause, whichever occurs earlier. |
Up to Approximately 3 Years
|
|
Progression-free survival (PFS)
Ramy czasowe: Up to Approximately 3 Years
|
PFS is defined as time from first study treatment to a documented disease progression according to RECIST Version 1.1 (or other assessment criteria), as determined by the investigator, or death due to any cause, whichever occurs earlier. |
Up to Approximately 3 Years
|
|
Overall Survival (OS)
Ramy czasowe: Up to Approximately 3 Years
|
OS is defined as time from first study treatment to death due to any cause. |
Up to Approximately 3 Years
|
|
Disease Control Rate
Ramy czasowe: Up to Approximately 3 Years
|
Disease Control Rate is defined as the percentage of participants with best overall response (BOR) of stable disease (SD), PR or better per investigator review according to RECIST version 1.1 criteria. |
Up to Approximately 3 Years
|
Współpracownicy i badacze
Sponsor
Śledczy
- Dyrektor Studium: ABBVIE INC., AbbVie
Daty zapisu na studia
Główne daty studiów
Rozpoczęcie studiów (Rzeczywisty)
Zakończenie podstawowe (Szacowany)
Ukończenie studiów (Szacowany)
Daty rejestracji na studia
Pierwszy przesłany
Pierwszy przesłany, który spełnia kryteria kontroli jakości
Pierwszy wysłany (Rzeczywisty)
Aktualizacje rekordów badań
Ostatnia wysłana aktualizacja (Rzeczywisty)
Ostatnia przesłana aktualizacja, która spełniała kryteria kontroli jakości
Ostatnia weryfikacja
Więcej informacji
Terminy związane z tym badaniem
Słowa kluczowe
Dodatkowe istotne warunki MeSH
- Choroby układu moczowo-płciowego
- Choroby narządów płciowych
- Choroby układu hormonalnego
- Nowotwory układu moczowo-płciowego
- Nowotwory według lokalizacji
- Nowotwory
- Choroby układu moczowo-płciowego kobiet
- Choroby układu moczowo-płciowego kobiet i powikłania ciąży
- Choroby narządów płciowych, kobiety
- Nowotwory gruczołów dokrewnych
- Choroby jajników
- Choroby przydatków
- Nowotwory narządów płciowych, kobiety
- Zaburzenia gonad
- Nowotwory jajnika
- Aminokwasy, peptydy i białka
- Białka
- Organiczne chemikalia
- Przeciwciała, monoklonalne, humanizowane
- Przeciwciała, monoklonalne
- Przeciwciała
- Immunoglobuliny
- Immunoproteiny
- Białka krwi
- Globuliny w surowicy
- Globuliny
- Kompleksy koordynacyjne
- Bewacyzumab
- Karboplatyna
Inne numery identyfikacyjne badania
- M25-760
- 2025-522209-40-00 (Ctis)
- 2025 (Grant/umowa NIH USA)
Plan dla danych uczestnika indywidualnego (IPD)
Planujesz udostępniać dane poszczególnych uczestników (IPD)?
Informacje o lekach i urządzeniach, dokumenty badawcze
Bada produkt leczniczy regulowany przez amerykańską FDA
Bada produkt urządzenia regulowany przez amerykańską FDA
produkt wyprodukowany i wyeksportowany z USA
Te informacje zostały pobrane bezpośrednio ze strony internetowej clinicaltrials.gov bez żadnych zmian. Jeśli chcesz zmienić, usunąć lub zaktualizować dane swojego badania, skontaktuj się z register@clinicaltrials.gov. Gdy tylko zmiana zostanie wprowadzona na stronie clinicaltrials.gov, zostanie ona automatycznie zaktualizowana również na naszej stronie internetowej .